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Abstract 
Background: While statin use has been associated with reduced prostate cancer (PC) 
aggressiveness, the impact of race and other patient characteristics on this association is not well 
understood. We examined the association between statin use and PC aggressiveness in 
Caucasians (CA) and African Americans (AA), and explored effect modification by health-
seeking behaviors associated with statin use. 
Methods: Of 1,955 cases from the North Carolina-Louisiana Prostate Cancer Project (PCaP), 
345 (18%) were classified as aggressive based on clinical criteria. Logistic regression was used 
to examine the association between statin use and PC aggressiveness, overall and stratified by 
race. Smoking and PSA screening were examined as effect modifiers of this association.  
Results: There was an inverse association between statin use and PC aggressiveness (OR 0.70; 
95%CI 0.54-0.91), with comparable effect estimates in both races. Statin use was associated with 
reduced odds ratios for aggressive PC in never-screened men (OR 0.71; 95%CI 0.43-1.18) and in 
men screened at low/recommended frequency (≤once/year; OR 0.62; 95%CI 0.42-0.91), with no 
association in men screened at high frequency (>once/year; OR 1.19; 95%CI 0.54-2.62). The 
inverse association between statins and aggressive PC was strongest in never smokers (OR 0.43; 
95%CI 0.25-0.74), attenuated in former smokers (OR 0.77; 95%CI 0.54-1.09), and absent in 
current smokers (OR 1.27; 95%CI 0.67-2.41). 
Conclusions: Statin use was associated with reduced PC aggressiveness, with strongest inverse 
associations in non-smokers and in men following screening recommendations. 
Impact: Health-seeking behaviors associated with statin use should be considered when 
examining the impact of statins on PC aggressiveness.  
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Introduction 
Prostate cancer is the most commonly diagnosed non-cutaneous cancer type in US males, and the 
second most common cause of male cancer deaths [1]. Aggressive disease characteristics at 
diagnosis, defined by biopsy Gleason sum, clinical stage and PSA level, are associated with 
increased prostate cancer-specific mortality [2]. As such, there is a need to identify factors which 
may impact the risk of aggressive prostate cancer. 
Statins, a class of cholesterol-lowering drugs, are used by approximately one in every four adult 
males in the US population [3]. While statin use is not associated with overall prostate cancer 
incidence [4-7], two meta-analyses have reported an inverse association between statin use and 
risk of aggressive prostate cancer [5, 8]. However, many of the studies contributing to these 
meta-analyses were limited by incomplete assessment of type and dose of statin and use of other 
cholesterol-lowering drugs, as well as patient characteristics including dietary cholesterol and 
saturated fat intake, smoking status and PSA screening history. In addition, these prior studies 
were conducted in predominantly Caucasian populations, and therefore the impact of race on 
these associations is unknown. 
Using the population-based North Carolina-Louisiana Prostate Cancer Project (PCaP), we 
examined associations between statin use, dose and type, and prostate cancer aggressiveness, 
overall and stratified by race. We explored PSA screening history as both a confounder and an 
effect modifier of the association between statin use and prostate cancer aggressiveness. In 
addition, we tested whether associations differed by smoking status, given that smoking is a 
known modifier of serum lipid levels. 
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Methods 
Study population 
The North Carolina-Louisiana Prostate Cancer Project (PCaP) is a population-based study of 
incident prostate cancer in two southern US states [9]. Men with a first diagnosis of 
histologically confirmed prostate cancer on or after July 1, 2004 were eligible to participate in 
PCaP if they were 40-79 years of age at diagnosis, could complete the study interview in 
English, did not live in an institution or nursing home, and were not cognitively impaired. 
Eligibility criteria also required men to self-identify as either African American/black (AA) or 
Caucasian/white (CA) in response to an open-ended question “what is your race?” Research 
protocols were approved by the institutional review boards at University of North Carolina, 
Louisiana State University Health Services Center, and Department of Defense CaP Research 
Program.  
Exposure assessment 
PCaP nurses administered a series of structured questionnaires that included baseline 
characteristics, PSA screening history, diet and medications, during an in-home visit conducted 
approximately 3 months after diagnosis [9]. PSA screening history was dichotomized as ever vs. 
never screened, with the never screened category including men who underwent PSA screening 
only within one year of diagnosis, in order to ensure that diagnostic PSA tests were not 
misclassified as PSA screening history. Among the ever screened, PSA screening frequency was 
calculated as the total number of PSA tests in the patient’s lifetime divided by the number of 
years since the first PSA test. PSA screening frequency was dichotomized as ≤1 PSA test per 
year versus >1 PSA test per year, given that prostate cancer screening guidelines in place at the 
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time of PCaP recruitment recommended annual PSA screening. The dietary assessment 
instrument was a modified National Cancer Institute (NCI) Diet History Questionnaire to which 
numerous Southern US foods were added. Men were asked to report dietary intake during the 12 
month period prior to prostate cancer diagnosis. Dietary cholesterol intake (mg per day) and the 
average percentage of calories obtained from saturated fat were calculated using NCI Diet Calc. 
Study participants gathered all prescription and non-prescription medications and supplements 
used in the two week period prior to interview and presented them to the nurse at the time of 
interview for documentation of current medication use, including type and dose. For the present 
analysis, we abstracted statin use [atorvastatin (lipitor, caduet), simvastatin (zocor, vytorin), 
rosuvastatin (crestor), lovastatin (altoprev, advicor), pravastatin (pravachol), fluvastatin (lescol)] 
and non-statin cholesterol-lowering drug use [niacin (niaspan, niacor), fibrate (gemfibrozil, 
tricor) and ezetimibe (ezetimibe, vytorin)]. Statin type was classified as hydrophilic 
(rosuvastatin, pravastatin) or lipophilic (atorvastatin, simvastatin, lovastatin, fluvastatin) [10]. 
Statin dose was converted to a simvastatin dose-equivalent, as previously described [11], and 
dichotomized as low/normal (≤20 mg simvastatin dose-equivalent) vs. high dose (>20 mg 
simvastatin dose-equivalent).  
Outcome assessment 
Clinical stage, biopsy Gleason sum, and PSA at diagnosis were abstracted from medical records. 
Prostate cancer aggressiveness was defined using these three variables as follows i) high 
aggressive (Gleason sum ≥8, or PSA >20 ng/ml, or (Gleason sum ≥7 and clinical stage T3-T4)), 
ii) low aggressive (Gleason sum <7 and clinical stage T1-T2 and PSA <10 ng/ml), ii) 
intermediate aggressive (all other cases), as described previously for PCaP [9]. Complete 
prostate cancer aggressiveness data were missing for 85 men, and these men were excluded from 
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our analysis. We also excluded men who were missing body mass index (BMI; n=21), smoking 
status (n=1) and PSA screening history (ever/never; n=196), resulting in 1,955 research subjects 
(n=1,037 CA and n=918 AA) eligible for the present analysis. 
Statistical analysis 
We examined differences in patient and tumor characteristics between CA and AA men, and 
between statin users and non-users, using chi-square tests for categorical variables, student’s t-
tests for continuous, normally-distributed variables and rank sum tests for continuous non-
normally distributed variables. 
Multivariable logistic regression was used to examine the association between statin use, dose 
and type, and prostate cancer aggressiveness (high vs. low/intermediate). We utilized a directed 
acyclic graph to select covariates and then performed backwards selection to build our final 
model which included age (continuous), race (AA, CA), site (NC, LA), BMI (continuous, log-
transformed), cholesterol intake (continuous, log-transformed), percent calories from saturated 
fat (continuous), smoking status (never, former, current), and PSA screening history (never, 
ever). When examining associations between hydrophilic statins and prostate cancer 
aggressiveness, we excluded lipophilic statin users, and vice versa. We conducted a sensitivity 
analysis excluding men who used non-statin cholesterol-lowering drugs (22% of statin users and 
7% of statin non-users). We also explored the effect of additionally adjusting models for 
frequency of PSA screening (never, ≤one PSA test per year, >one PSA test per year (in place of 
PSA screening history ever/never)), education level (less than high school, high school graduate, 
college graduate or some college), annual household income (<$20,000, $20,000-$50,000, 
$50,000-$80,000, >$80,000), and family history of prostate cancer in a first degree relative (yes, 
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no), in the subset of men for whom all of these data were available (n=1,507). In order to 
examine smoking status and PSA screening frequency as potential effect modifiers of the 
association between statin use and prostate cancer aggressiveness, we conducted stratified 
analysis by each of these health-seeking behaviors. We tested for interaction between smoking 
status and statin use for predicting prostate cancer aggressiveness by incorporating a cross 
product term into the logistic regression model, and testing its significance using the Wald test. 
Statistical analyses were performed using Stata 13.1 (Stata, Corp., College Station, TX, USA).  
Statistical significance was two-sided with p < 0.05. 
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Results 
Characteristics of study participants by race  
Incident prostate cancer cases in this study included 1,037 CAs (n=487 from NC and n=550 from 
LA) and 918 AAs (n=424 from NC and n=494 from LA; Table 1). AAs were younger at 
diagnosis than CAs (62 vs. 64 mean years of age; p<0.0001). While clinical stage did not differ 
by race (p=0.863), AAs had a higher median PSA level than CAs (6.3 vs. 5.2 ng/ml; p<0.0001; 
Table 1) and were more likely to have a high biopsy Gleason sum (≥4+3; 22% vs. 18%; 
p=0.025) and aggressive prostate cancer (20% vs. 15%; p=0.003).  
AAs were less likely than CAs to have a history of PSA screening (64% vs. 85%; p<0.0001), 
although the frequency of PSA screening among screened men did not differ by race (p=0.267). 
While the prevalence of family history of prostate cancer in a first degree relative did not differ 
by race (p=0.131), AAs were less highly educated (p<0.0001), reported a lower annual 
household income (p<0.0001) and were more likely to be current smokers than CAs (22% vs. 
9%; p<0.0001; Table 1). 
The prevalence of obesity, defined as BMI≥30 kg/m2, did not differ by race (p=0.473). However, 
despite lower prevalence of cardiovascular disease (13% vs. 19%; p<0.0001), AAs were more 
likely than CAs to have co-morbid health conditions (Charlson index ≥1; 54% vs. 47%; 
p=0.001), including diabetes (27% vs. 17%; p<0.0001). In addition, AAs had higher dietary 
cholesterol intake (302 vs. 262 mg/day; p<0.0001), although the percentage of calories obtained 
from saturated fat was higher in CAs (11.2% vs. 10.0%; p<0.0001; Table 1). 
Characteristics of study participants by statin use 
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Of a total of 1,955 patients, 729 (37%) were statin users at the time of interview, with the 
majority of statin users taking either simvastatin (38%) or atorvastatin (34% ), and the remainder 
using rosuvastatin (10%), pravastatin (9%), lovastatin (5%) or fluvastatin (2%). Statin type or 
dose did not differ by race (data not shown). Statin users were older than non-users (65 vs. 62 
mean years of age at diagnosis; p<0.0001), and were more likely to be CA (57% vs. 43%; 
p=0.006). While there were no significant differences in biopsy Gleason sum or clinical stage by 
statin use (p=0.105 and p=0.089, respectively), statin users had lower median PSA level (5.3 vs. 
5.8 ng/ml; p=0.0001) and a lower frequency of aggressive prostate cancer (15% vs. 19%; 
p=0.016; Table 2).  
Statin users were more likely to report a history of PSA screening, relative to non-users (85% vs. 
72%; p<0.0001), although the frequency of PSA screening among screened men did not differ by 
statin use (p=0.198). While there was no difference in the prevalence of family history of 
prostate cancer, level of education or annual household income by statin use (all p>0.198), statin 
users were less likely to be current smokers (11% vs. 18%; p<0.0001; Table 2). 
Relative to non-users, statin users were more likely to be obese (BMI≥30 kg/m2; 44% vs. 34%; 
p<0.0001) and have a co-morbid condition (Charlson index ≥1; 62% vs. 42%; p<0.0001), 
including diabetes (31% vs. 15%, p<0.0001) and cardiovascular disease (29% vs. 8%; 
p<0.0001). However, statin users had lower dietary cholesterol intake (269 vs. 288 mg/day; 
p=0.0002), although there was no difference in the percentage of calories obtained from 
saturated fat between statin users and non-users (p=0.564). Use of non-statin cholesterol-
lowering drugs (niacin, fibrates or ezetimibe) was higher among statin users, relative to non-
users (22% vs. 7%; p<0.0001).  
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We also examined differences in statin users vs. non-users stratified by race, and found that these 
aforementioned differences in tumor and patient characteristics between statin users and non-
users were observed in both CAs and AAs (Supplementary Table 1). 
Associations between statin use and prostate cancer aggressiveness 
Of 345 (18%) incident cases of aggressive prostate cancer, 109 (32%) occurred in statin users 
and 236 (68%) occurred in non-users. For comparison, of 1,610 (82%) incident cases of non-
aggressive prostate cancer, 620 (39%) occurred in statin users and 990 (61%) occurred in non-
users. After adjusting for potential confounders, statin use was associated with a significantly 
reduced odds ratio (OR) for aggressive prostate cancer (OR 0.70; 95% CI 0.54-0.91; Table 3), 
with similar effect estimates in CAs (OR 0.66; 95% CI 0.45-0.96) and AAs (OR 0.75; 95% CI 
0.51-1.09), although the association in AAs was not statistically significant. We observed similar 
inverse associations in men taking a low/normal statin dose (OR 0.68; 95% CI 0.47-0.99) and in 
men taking a high statin dose (OR 0.72; 95% CI 0.52-0.98), with no evidence for a dose-
response relationship. Finally, while there was a suggestion of a stronger protective effect with 
hydrophilic relative to lipophilic statins (OR 0.49; 95% CI 0.27-0.88 and OR 0.74; 95% CI 0.56-
0.98, respectively), these estimates were somewhat imprecise due to low numbers of men using 
hydrophilic statins and should be interpreted cautiously. Excluding men using non-statin 
cholesterol-lowering drugs or additionally adjusting our models for PSA screening frequency, 
education level, annual household income and family history of prostate cancer did not alter our 
findings (Supplementary Tables 2 and 3, respectively). 
Impact of health-seeking behaviors on the association between statin use and prostate cancer 
aggressiveness 
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In order to further explore possible PSA screening-related detection biases, we examined PSA 
screening frequency as an effect modifier of the association between statins and prostate cancer 
aggressiveness. We observed an inverse association between statin use and prostate cancer 
aggressiveness in men who were screened annually or less frequently (OR 0.62; 95% CI 0.42-
0.91) and a similar, albeit slightly attenuated, inverse association in men who had never 
undergone PSA screening (OR 0.71; 95% CI 0.43-1.18; Table 4). However, there was no 
evidence for an association between statin use and prostate cancer aggressiveness in men who 
were screened more frequently than once a year (OR 1.19; 95% CI 0.54-2.63).  
Smoking increases low-density and total cholesterol levels and decreases high-density 
cholesterol levels [12, 13], potentially offsetting the cholesterol-lowering effect of statin use. 
Indeed, we found no association between statin use and prostate cancer aggressiveness in current 
smokers (OR 1.27; 95% CI 0.67-2.41). In contrast, there was a strong inverse association 
between statin use and prostate cancer aggressiveness in never smokers (OR 0.43; 95% CI 0.25-
0.74), with a slightly attenuated protective effect in former smokers (OR 0.77; 95% CI 0.54-1.09; 
Table 5), and a significant interaction between smoking status and statin use in predicting 
prostate cancer aggressiveness (Wald test; p=0.0003). 
   
13 
 
Discussion 
Using data from the population-based North Carolina-Louisiana Prostate Cancer Study, we 
report an inverse association between statin use and aggressive prostate cancer. These findings 
are in agreement with the ~20-25% reduced risk of aggressive prostate cancer in statin users 
relative to non-users reported by two meta-analyses [5, 8]. As such, our findings strengthen 
existing rationale to explore a role for statins in aggressive prostate cancer prevention.  
One important consideration when studying the impact of statin use on prostate cancer 
aggressiveness is that detection bias arising from higher rates of PSA screening in statin users 
could produce an inverse association with aggressive disease, irrespective of a causal 
relationship [14, 15]. In the present study, we found that adjusting our models for PSA screening 
frequency did not substantially impact our estimates. However, analyses stratified by PSA 
screening frequency showed a null association between statin use and prostate cancer 
aggressiveness in men who were screened more often than once a year, potentially attributable to 
underlying health issues which may have driven the higher-than-recommended frequency of 
PSA screening in this group. On the other hand, we observed a similar magnitude of inverse 
association between statin use and prostate cancer aggressiveness in men screened at low or 
recommended frequency (i.e., annually) and in unscreened men, suggesting that the association 
between statin use and prostate cancer aggressiveness cannot be completely explained by PSA 
screening-related detection bias. In support of these findings, inverse associations between statin 
use and aggressive prostate cancer have been reported both in European populations with very 
low screening rates [16] and in US populations with higher screening rates [17]. Moreover, an 
analysis of simulated datasets with different PSA screening frequencies suggested that detection 
bias is unlikely to explain the association between statin use and reduced risk of aggressive 
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prostate cancer [15]. As such, while the potential for detection bias should be considered, our 
findings, in addition to those from populations with different PSA screening frequencies [19], 
support a true association between statin use and aggressive prostate cancer. 
In addition to differences in PSA screening behaviors, characteristics of statin users differ from 
those of non-users in a variety of ways. Data from the present study show that obesity and 
diabetes, both associated with increased prostate cancer-specific mortality [20, 21], were more 
prevalent among statin users. On the other hand, we observed that statin use was associated with 
health-seeking behaviors, as indicated by the higher prevalence of PSA screening, lower 
prevalence of smoking and reduced dietary cholesterol intake, relative to non-users. These 
health-seeking behaviors themselves have been associated with reduced risk of aggressive 
prostate cancer [14, 22-26], potentially giving rise to a “healthy-user” bias whereby the 
association between statin use and prostate cancer aggressiveness could be explained by the 
health-seeking behaviors of statin users, and not statin use per se [27]. In the present analysis, we 
found that adjusting our models for these health-seeking behaviors did not substantially impact 
our estimates. However, analyses stratified on smoking status revealed a strong inverse 
association between statin use and prostate cancer aggressiveness in never smokers, a slightly 
attenuated effect in former smokers, and no association in current smokers. Given that the impact 
of statins on prostate cancer may be mediated at least in part via their cholesterol-lowering 
properties [18], a smoking-related increase in cholesterol level [12, 13] could potentially offset 
the protective effect of statins on prostate cancer aggressiveness. If confirmed in future studies, 
these findings may highlight the importance of smoking cessation to maximize the protective 
effect of statins on prostate cancer aggressiveness, in addition to the established role of smoking 
cessation in cardiovascular disease risk reduction. 
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Our findings should be considered in light of the strengths and limitations of this study. First, 
statin use was captured at the time of interview, with no information regarding the timing of 
statin initiation relative to prostate cancer diagnosis. However, given that the majority of our 
study population was interacting with the health care system prior to prostate cancer diagnosis 
(75% of individuals had a history of PSA screening), it is likely that the majority of men 
indicated for statin therapy would have initiated statins before diagnosis. Indeed, a previous 
study reported similar rates of statin use before and after prostate cancer diagnosis [28], 
suggesting that the majority of post-diagnosis statin users were also users prior to diagnosis. 
Moreover, any potential misclassification of unexposed individuals (i.e., pre-diagnosis non-users 
who initiated statin use after diagnosis) as exposed individuals (i.e., pre-diagnosis statin users) 
would likely bias our estimates towards the null. As such, our study may have underestimated 
the strength of the association between pre-diagnosis statin use and prostate cancer 
aggressiveness. In addition, while we did not have access to data for duration of use or adherence 
to statin therapy, the type and dose of statin and non-statin cholesterol-lowering drugs was 
documented by a trained nurse, thus improving the accuracy of our exposure data. Second, while 
serum cholesterol measurements were unavailable, dietary cholesterol and saturated fat intake 
was available for all study participants, and these dietary factors are important determinants of 
serum cholesterol level [29]. Third, observational studies examining the association between 
statin use and prostate cancer are susceptible to confounding by indication, given that statin use 
is not randomized. However, an important strength of this study is our comprehensive 
assessment of clinical and demographic characteristics, in addition to health-seeking behaviors of 
statin users and non-users, and adjustment for these potential confounders in our analysis.  
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In summary, we report an inverse association between statin use and aggressive prostate cancer 
in both Caucasians and African Americans. Differences in patient characteristics and health-
seeking behaviors by statin use should be an important consideration for future observational 
studies of statin use and prostate cancer, although our findings suggest that detection bias arising 
from higher rates of PSA screening in statin users does not entirely explain the inverse 
association between statin use and prostate cancer aggressiveness. The stronger protective effect 
of statin use in non-smokers requires confirmation in other studies, but suggests that increased 
efforts to reduce smoking rates in this population are warranted. Statins are well-tolerated, cost-
effective and widely-prescribed cholesterol-lowering drugs, with proven benefits for 
cardiovascular disease prevention [30]. Given that cardiovascular disease and cancer are the two 
most common causes of mortality in the US [31], with prostate cancer the second most common 
cause of cancer death in US men [1], understanding the role of statins in aggressive prostate 
cancer prevention will have important public health impact.  
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Table 1: Demographic and tumor characteristics of Caucasian and African American prostate cancer 
cases in the North Carolina-Louisiana Prostate Cancer Project 
 Caucasian (n=1,037) 
African 
American 
(n=918) 
p value 
Age at diagnosis, mean (SD) 64 (8) 62 (8) <0.0001 
Site    
North Carolina 487 (47) 424 (46) 0.732 Louisiana 550 (53) 494 (54) 
Clinical stage    
T1 580 (56) 517 (56) 0.863 T2-T4 457 (44) 401 (44) 
PSA (ng/ml), median (IQR) 5.2 (4.1-7.5) 6.3 (4.5-10.7) <0.0001 
Biopsy Gleason sum    
≤3+4 846 (82) 709 (78) 0.025 ≥4+3 188 (18) 203 (22) 
Aggressive prostate cancer    
Low/Intermediate 879 (85) 731 (80) 0.003 High 158 (15) 187 (20) 
PSA screening history    
Never 158 (15) 328 (36) <0.0001 Ever 879 (85) 590 (64) 
PSA screening frequency (among ever 
screened)a    
≤1 test per year 609 (78) 377 (75) 0.267 >1 test per year 171 (22) 123 (25) 
Family history of prostate cancer (first degree 
relative)b    
No 722 (75) 609 (72) 0.131 Yes 237 (25) 235 (28) 
Education    
Less than high school 96 (9) 263 (29) 
<0.0001 High school graduate 221 (21) 259 (28) 
College graduate or some college 720 (69) 395 (43) 
Incomec    
<$20,000 97 (10) 281 (33) 
<0.0001 $20,000-$50,000 281 (30) 323 (38) $50,000-$80,000 231 (24) 137 (16) 
>$80,000 339 (36) 104 (12) 
Smoking status    
Never 382 (37) 279 (30) 
<0.0001 Former 561 (54) 439 (48) 
Current 94 (9) 200 (22) 
BMI (kg/m2)    
<30 644 (62) 568 (62) 0.917 ≥30 393 (38) 350 (38) 
Charlson co-morbidity index    
0 557 (54) 436 (47) 0.006 
23 
 
≥1 480 (46) 482 (53) 
Cardiovascular disease    
No 840 (81) 795 (87) <0.0001 Yes 192 (19) 114 (13) 
Diabetes    
No 863 (84) 676 (74) <0.0001 Yes 170 (16) 238 (26) 
Dietary cholesterol intake (mg/day),  
median (IQR) 262 (180-355) 302 (209-447) <0.0001 
Percent saturated fat intake, mean (SD) 11.2 (2.7) 10.0 (2.6) <0.0001 
Non-statin cholesterol-lowering drug use    
None 868 (84) 850 (93) <0.0001 Niacin/Fibrate/Ezetimibe 169 (16) 68 (7) 
aPSA screening frequency was missing for 99 Caucasian and 90 African American men; bFamily history 
was missing for 78 Caucasian and 74 African American men; cIncome was missing for 13 Caucasian and 
30 African American men while 76 Caucasian and 43 African American men refused to answer this 
question   
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Table 2: Demographic and tumor characteristics of statin users and non-users in the North Carolina-
Louisiana Prostate Cancer Project 
 Statin non-users (n=1,226) 
Statin users  
(n=729) p value 
Age at diagnosis, mean (SD) 62 (8) 65 (7) <0.0001 
Race    
Caucasian 621 (51) 416 (57) 0.006 African American 605 (49) 313 (43) 
Site    
North Carolina 592 (48) 319 (44) 0.052 Louisiana 634 (52) 410 (56) 
Clinical stage    
T1 706 (58) 391 (54) 0.089 T2-T4 520 (42) 338 (46) 
PSA, median (IQR) 5.7 (4.3-9.6) 5.3 (4.2-7.7) 0.0001 
Biopsy Gleason sum    
≤3+4 961 (79) 594 (82) 0.105 ≥4+3 259 (21) 132 (18) 
Aggressive prostate cancer    
Low/Intermediate 990 (81) 620 (85) 0.016 High 236 (19) 109 (15) 
PSA screening    
Never 365 (30) 121 (17) <0.0001 Ever 861 (70) 608 (83) 
PSA screening frequency (among ever 
screened)a    
≤1 test per year 590 (79) 396 (75) 0.098 >1 test per year 160 (21) 134 (25) 
Family history of prostate cancer (first degree 
relative)b    
No 827 (73) 504 (76) 0.198 Yes 309 (27) 163 (24) 
Education    
Less than high school 293 (19) 120 (16) 
0.200 High school graduate 303 (25) 177 (24) 
College graduate or some college 684 (56) 431 (59) 
Incomec    
<$20,000 246 (22) 132 (20) 
0.403 $20,000-$50,000 368 (33) 236 (35) $50,000-$80,000 225 (20) 143 (21) 
>$80,000 287 (25) 156 (23) 
Smoking status    
Never 417 (34) 244 (33) 
<0.0001 Former 593 (48) 407 (56) 
Current 216 (18) 78 (11) 
BMI (kg/m2)    
<30 807 (66) 405 (56) <0.0001 ≥30 419 (34) 324 (44) 
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Charlson co-morbidity index    
0 713 (58) 280 (38) <0.0001 ≥1 513 (42) 449 (62) 
Cardiovascular disease    
No 1,122 (92) 513 (71) <0.0001 Yes 96 (8) 210 (29) 
Diabetes    
No 1,042 (85) 497 (69) <0.0001 Yes 181 (15) 227 (31) 
Dietary cholesterol intake (mg/day) 288 (198-408) 269 (180-369) 0.0002 
Percent saturated fat intake, mean (SD) 10.6 (2.7) 10.7 (2.8) 0.564 
Non-statin cholesterol-lowering drug use    
None 1,146 (93) 572 (78) <0.0001 Niacin/Fibrate/Ezetimibe 80 (7) 157 (22) 
aPSA screening frequency was missing for 111 statin non-users and 78 statin users; bFamily history 
missing for 90 statin non-users and 62 statin users; cIncome was missing for 28 statin non-users and 15 
statin users, while 72 statin non-users and 47 statin users refused to answer this question  
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Table 3: Associations between statin use, dose and type and prostate cancer aggressiveness, overall and 
stratified by race 
 All Caucasian African American 
 n, cases (aggressive) OR* (95% CI) 
n, cases 
(aggressive) OR* (95% CI) 
n, cases 
(aggressive) OR* (95% CI) 
Statin use       
No use 1,226 (236) 1.00 (ref) 621 (103) 1.00 (ref) 605 (133) 1.00 (ref) 
Use 729 (109) 0.70 (0.54-0.91) 416 (55) 0.66 (0.45-0.96) 313 (54) 0.75 (0.51-1.09) 
Statin dosea       
No use 1,226 (236) 1.00 (ref) 621 (103) 1.00 (ref) 605 (133) 1.00 (ref) 
Low/normal 299 (43) 0.68 (0.47-0.99) 179 (25) 0.70 (0.43-1.15) 120 (18) 0.64 (0.37-1.13) 
High 430 (66) 0.72 (0.52-0.98) 237 (30) 0.63 (0.40-1.10) 193 (36) 0.81 (0.53-1.26) 
Statin typeb       
No use 1,226 (236) 1.00 (ref) 621 (103) 1.00 (ref) 605 (133) 1.00 (ref) 
Hydrophilic 129 (14) 0.49 (0.27-0.88) 82 (8) 0.42 (0.19-0.93) 47 (6) 0.57 (0.24-1.48) 
Lipophilic 598 (94) 0.74 (0.56-0.98) 334 (47) 0.72 (0.48-1.07) 264 (47) 0.78 (0.52-1.15) 
*adjusted for age, race (except for analyses stratified by race), site, BMI, cholesterol intake, percent 
saturated fat intake, smoking status, PSA screening history 
alow/normal dose≤20mg simvastatin or equivalent; high dose>20mg simvastatin or equivalent 
bHydrophilic=rosuvastatin, pravastatin; Lipophilic=atorvastatin, simvastatin, lovastatin, fluvastatin 
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Table 4: Associations between statin use and prostate cancer aggressiveness, stratified by PSA screening 
frequency 
 Total cases, n Aggressive, n (%) OR* (95%CI) 
Never screened    
Statin non-users 365 102 (28) 1.00 (ref) 
Statin users 121 28 (23) 0.71 (0.43-1.18) 
≤ 1 PSA tests per year    
Statin non-users 590 96 (16) 1.00 (ref) 
Statin users 396 52 (13) 0.62 (0.42-0.91) 
> 1 PSA tests per year    
Statin non-users 160 37 (10) 1.00 (ref) 
Statin users 134 28 (13) 1.19 (0.54-2.62) 
*adjusted for age, race, site, BMI, cholesterol intake, percent saturated fat intake, smoking status 
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Table 5: Associations between statin use and prostate cancer aggressiveness, stratified by smoking status  
 Total cases, n Aggressive, n (%) OR* (95%CI) 
Never smokers    
Statin non-users 417 68 (16) 1.00 (ref) 
Statin users 244 23 (9) 0.43 (0.25-0.74) 
Former smokers    
Statin non-users 593 113 (19) 1.00 (ref) 
Statin users 407 65 (16) 0.77 (0.54-1.09) 
Current smokers    
Statin non-users 216 55 (25) 1.00 (ref) 
Statin users 78 21 (27) 1.27 (0.67-2.41) 
*adjusted for age, race, site, BMI, cholesterol intake, percent saturated fat intake, PSA screening history 
 
